{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:57:13Z","timestamp":1782269833883,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Some patients with relapsed\/refractory Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) are not considered suitable for stem cell transplant (<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1\u00b78\u00a0mg\/kg intravenously once every 3\u00a0weeks) in 60 patients (aged \u226518\u00a0years) with CD30\u2010positive relapsed\/refractory <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>, a history of \u22651 prior systemic chemotherapy regimen, who were considered unsuitable for <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>\/multi\u2010agent chemotherapy. Primary endpoint was overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>) per independent review facility (<jats:styled-content style=\"fixed-case\">IRF<\/jats:styled-content>). Secondary endpoints included duration of response (<jats:styled-content style=\"fixed-case\">DOR<\/jats:styled-content>), progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) per <jats:styled-content style=\"fixed-case\">IRF<\/jats:styled-content>, overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>), proportion proceeding to <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> and safety. The <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 50%, with 12% CR; 47% proceeded to <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>. Median <jats:styled-content style=\"fixed-case\">DOR<\/jats:styled-content> was 4\u00b76\u00a0months and median duration of CR was 6\u00b71\u00a0months. After a median follow\u2010up of 6\u00b79 and 16\u00b76\u00a0months, median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> were 4\u00b78\u00a0months (95% confidence interval, 3\u00b70\u20135\u00b73) and not reached, respectively; estimated OS rate was 86% at 12\u00a0months. Most common adverse events (\u226510%) were peripheral neuropathy (35%), pyrexia (18%), diarrhoea and neutropenia (each 10%). Brentuximab vedotin showed notable activity with a safety profile consistent with known toxicities, and may act as a bridge to <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>, enabling high\u2010risk patients who achieve suboptimal response to frontline\/salvage chemotherapy\/radiotherapy to receive potentially curative <jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15539","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T07:22:15Z","timestamp":1535700135000},"page":"400-410","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prospective study of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi\u2010agent chemotherapy"],"prefix":"10.1111","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-2674","authenticated-orcid":false,"given":"Jan","family":"Walewski","sequence":"first","affiliation":[{"name":"Department of Lymphoid Malignancy Maria Sklodowska\u2010Curie Institute \u2013 Oncology Centre Warszawa Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[{"name":"Department of Haematology Medical University of Gda\u0144sk Gda\u0144sk Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noppadol","family":"Siritanaratkul","sequence":"additional","affiliation":[{"name":"Department of Medicine Siriraj Hospital Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guner Hayri","family":"Ozsan","sequence":"additional","affiliation":[{"name":"Department of Haematology Dokuz Eylul University Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhit","family":"Ozcan","sequence":"additional","affiliation":[{"name":"Department of Haematology Ankara University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suporn","family":"Chuncharunee","sequence":"additional","affiliation":[{"name":"Oncology Centre Ramathibodi Hospital Mahidol University Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Sim","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Medicine Hospital Pulau Pinang Pulau Pinang Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Haematology Jagiellonian University Krak\u00f3w Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Koren","sequence":"additional","affiliation":[{"name":"Department of Haematology Charles University Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Paszkiewicz\u2010Kozik","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancy Maria Sklodowska\u2010Curie Institute \u2013 Oncology Centre Warszawa Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Singh","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Huebner","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University Hospital Cologne Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University Hospital Cologne Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.07.005"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"Abstract 583","DOI":"10.1182\/blood.V126.23.583.583","article-title":"Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow\u2010up of a phase 1 study (CA209\u2010039)","volume":"126","author":"Ansell S.M.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm090"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0288"},{"key":"e_1_2_8_7_1","first-page":"98","article-title":"Brentuximab vedotin (BV) in patients who are ineligible for autologous stem cell transplant (ASCT) with relapsed or refractory Hodgkin lymphoma (RRHL): a UK and Germany Retrospective Study","volume":"101","author":"Br\u00f6ckelmann P.J.","year":"2016","journal-title":"Haematologica"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1834.1834"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.326"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_72"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu181"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14898"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1425"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0133"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1109.1109"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.069393"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.491137"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2192-z"},{"key":"e_1_2_8_24_1","unstructured":"Howlader N. Noone A. Krapcho M. Bishop K. Altekruse S. Kosary C. Yu M. Ruhl J. Tatalovich Z. Mariotto A. Lewis D. Chen H. Feuer E.&Cronin K.(eds) (2016)SEER Cancer Statistics Review 1975\u20132013 National Cancer Institute.Bethesda MD http:\/\/seer.cancer.gov\/csr\/1975_2013\/ based on November 2015 SEER data submission posted to the SEER web site April 2016."},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"126","author":"LaCasce A.S.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.14735\/amko2014424"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.775434"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.136408"},{"key":"e_1_2_8_29_1","first-page":"3736","article-title":"The anti\u2010CD30 monoclonal antibody SGN\u201030 promotes growth arrest and DNA fragmentation in\u00a0vitro and affects antitumor activity in models of Hodgkin's disease","volume":"62","author":"Wahl A.F.","year":"2002","journal-title":"Cancer Research"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-085159"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0227"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T18:26:29Z","timestamp":1694802389000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/bjh.15539"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15539","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"2018-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}